- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01775462
Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (ECP-002)
A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Hopital Necker-Enfants Malades
-
-
-
-
Bavaria
-
Erlangen, Bavaria, Germany, 91054
- University Hospital Erlangen
-
-
-
-
-
Milan, Italy, 20157
- Azienda Ospedaliera-Polo Universitario "Luigi Sacco"
-
-
-
-
-
Cardiff, United Kingdom, CF14 4XW
- University Hospital of Wales
-
-
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects for study drug administration must meet all of the following criteria to be enrolled:
- Male with genetic confirmation of an XLHED diagnosis.
- Subject must be at least 48 hours age and no older than 14 days.
- Subject will have reached term (defined as 37 weeks gestation or older) prior to receiving first dose study drug.
- Written informed consent of both parents (if reasonably available) must be obtained for treatment of their XLHED-affected male infant.
- Neither mother nor the XLHED-affected male infant known to have received an investigational study drug in the 9 months prior to study subject enrollment in this study.
- No major medical issues that the PI considers a contraindication to participation.
Siblings of subjects receiving study drug must meet all of the following criteria to be enrolled in the natural history sub-study (no age limit involved):
- Provide written informed consent/assent.
- A full or half-sibling of a study subject where the study subject has received at least one dose of study drug in the Phase 2 XLHED Neonate Study and has not yet completed the study.
- No major medical issues that the investigator considers contraindications to participation.
Exclusion Criteria:
Subjects for study drug administration who meet any of the following criteria cannot be enrolled in this study:
1. Medically significant postnatal complications or congenital anomalies outside of those considered to be associated with the diagnosis of XLHED.
Siblings of subjects receiving study drug who meet any of the following criteria cannot be enrolled in the natural history sub-study:
- Known hypersensitivity to pilocarpine or pilocarpine-like muscarinic agonists.
- Known hypersensitivity to lidocaine or lidocaine-like agents.
- Presence of pacemaker.
- Subjects who are not able or are not willing to comply with the procedures of this protocol.
- Subject has a condition, which in the opinion of the investigator would not allow for safe conduct of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EDI200, 3mg/kg
Five doses of EDI200 given at 3 mg/kg twice weekly
|
3 or 10 mg/kg of EDI200
Other Names:
|
Experimental: EDI200, 10 mg/kg
Five doses of EDI200 given at 10 mg/kg twice weekly
|
3 or 10 mg/kg of EDI200
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of adverse events
Time Frame: Up to 6 months after dosing
|
Up to 6 months after dosing
|
To assess the antibody response to EDI200
Time Frame: Up to 6 months after dosing
|
Up to 6 months after dosing
|
Area under the concentration time curve to the end of the dosing period (AUC0-tau) of EDI200
Time Frame: Pre-dose and 15 minutes and 3, 8, 24 and 48 hours post-dose 1 and pre-dose and 15 minutes and 3, 18, 48 and 168 hours post-dose 5
|
Pre-dose and 15 minutes and 3, 8, 24 and 48 hours post-dose 1 and pre-dose and 15 minutes and 3, 18, 48 and 168 hours post-dose 5
|
Peak plasma concentration (Cmax) of EDI200
Time Frame: Pre-dose and 15 minutes and 3, 8, 24 and 48 hours post-dose 1 and pre-dose and 15 minutes and 3, 18, 48 and 168 hours post-dose 5
|
Pre-dose and 15 minutes and 3, 8, 24 and 48 hours post-dose 1 and pre-dose and 15 minutes and 3, 18, 48 and 168 hours post-dose 5
|
Time at which maximum concentration is observed (Tmax) of EDI200
Time Frame: Pre-dose and 15 minutes and 3, 8, 24 and 48 hours post-dose 1 and pre-dose and 15 minutes and 3, 18, 48 and 168 hours post-dose 5
|
Pre-dose and 15 minutes and 3, 8, 24 and 48 hours post-dose 1 and pre-dose and 15 minutes and 3, 18, 48 and 168 hours post-dose 5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the pharmacodynamics/efficacy (growth and development) of EDI200
Time Frame: Baseline and 2, 4 and 6 months
|
Baseline and 2, 4 and 6 months
|
To assess the pharmacodynamics/efficacy (dentition) of EDI200
Time Frame: Baseline and post-six months (extension study)
|
Baseline and post-six months (extension study)
|
To assess the pharmacodynamics/efficacy (craniofacial development) of EDI200
Time Frame: Baseline and 6 months
|
Baseline and 6 months
|
To assess the pharmacodynamics/efficacy (sweat duct density) of EDI200
Time Frame: Baseline and 2 and 6 months
|
Baseline and 2 and 6 months
|
To assess the pharmacodynamics/efficacy (sweat rate) of EDI200
Time Frame: Baseline and 2 and 6 months
|
Baseline and 2 and 6 months
|
To assess the pharmacodynamics/efficacy (Dry eye signs and symptoms) of EDI200
Time Frame: Baseline and 2 and 6 months
|
Baseline and 2 and 6 months
|
To assess the pharmacodynamics/efficacy (thermoregulation) of EDI200
Time Frame: Baseline and study day 21
|
Baseline and study day 21
|
To assess the pharmacodynamics/efficacy (molecular expression profile of skin biopsy tissue) of EDI200
Time Frame: Baseline, study days 1 and 15
|
Baseline, study days 1 and 15
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kenneth Huttner, MD, PhD, Edimer Pharmaceuticals
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ECP-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on X-Linked Hypohidrotic Ectodermal Dysplasia
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal DysplasiaUnited States
-
Edimer PharmaceuticalsActive, not recruitingX-linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
University Hospital ErlangenEdimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal DysplasiaGermany
-
Edimer PharmaceuticalsCompletedX Linked Hypohidrotic Ectodermal DysplasiaUnited States
-
EspeRare FoundationIqvia Pty Ltd; Pierre Fabre MedicamentRecruitingX-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)United States, Spain, France, Germany, Italy, United Kingdom
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal Dysplasia | Hypohidrotic Ectodermal DysplasiaUnited States
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal Dysplasia | Hypohidrotic Ectodermal DysplasiaSpain
-
Edimer PharmaceuticalsCompleted
-
Edimer PharmaceuticalsCompletedX-Linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
Edimer PharmaceuticalsCompletedHypohidrotic Ectodermal Dysplasia | X-Linked Hypohidrotic Ectodermal DysplasiaUnited States
Clinical Trials on EDI200
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal DysplasiaUnited States
-
Edimer PharmaceuticalsActive, not recruitingX-linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy